:quality(80)/business-review.eu/wp-content/themes/business-review/assets/images/no-picture.jpg)
2nd edition, November 21th, 2013, Cismigiu Hotel, Lipscani Hall
ATTENDANCE BY INVITATION ONLY
As Romania has committed on a program of repaying debts to the pharma industry, what will be the impact on this sector?
The pharma industry is set to post only a slight growth in Romania, given the reduced availability of medical services for patients and the negative impact of the claw back tax. Producers are also calling for a redesign of the claw-back mechanism, urging that it should take into account only the producer price.
Find out about upcoming legislation changes and how they will affect the pharma industry at the second edition of Pharmaceutical Roundtable.
Program
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
15.00 – 15.30 Registration
15:30 – 15:45 Welcome address: Valeriu Stoica, Founding Partner, STOICA & Asociaţii
15.45 – 17.30 Panel discussions
Topics:
- Clawback – outlook for 2014
- Clawback related case-law and administrative practices
- Compensated medicine debt: 1.3 billion euro
- Medicine’s prices dynamic. Local vs. imports
- Pharmaceutical market perspectives
Moderator:
- Valeriu Stoica, Founding Partner, STOICA & Asociaţii
Proposed speakers:
- Adrian Pană, Secretary of State, Ministry of Health
- Cristian Buşoi, President, National Health Insurance House
- Amelia Dinu, General Manager, BBraun Medical Romania
- Dragoş Bogdan, Partner, STOICA & Asociaţii
- Petru Crăciun, General Manager, Cegedim
- Laurentiu Mihai, Executive Director, Romanian Generic Medicines Manufacturers Association (APMGR)
- Luca Visini, CEO, Ely Lilly, ARPIM Member
17.30 – 18.00 Final Questions & Answers
18.00 – 19.00 Networking Cocktail
ATTENDANCE BY INVITATION ONLY